<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33458">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01904019</url>
  </required_header>
  <id_info>
    <org_study_id>ORTHO.CR.E16</org_study_id>
    <nct_id>NCT01904019</nct_id>
  </id_info>
  <brief_title>ARPE Prosthesis Study</brief_title>
  <official_title>Trapezio-metacarpal Arthroplasty: Comparison of ARPE Prosthesis With the Literature</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biomet, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biomet Belgium BVBA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biomet, Inc.</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of functional outcome at 3 years after trapezio-metacarpal arthroplasty with
      trapeziectomy and trapeziectomy with ligament reconstruction and tendon interposition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to compare functional outcome at 3 years after trapezio-metarcarpal
      arthroplasty with trapeziectomy and trapeziectomy with ligament reconstruction and tendon
      interposition. Literature values obtained by a recently published meta analysis1 will be
      used.

      Secondary objectives are:

        -  to compare functional outcome at 1 and at 5 years after trapezio-metarcarpal
           arthroplasty with trapeziectomy and trapeziectomy with ligament reconstruction and
           tendon interposition

        -  to determine pre- and postop HR QOL

        -  Incidence of RLL at each follow up time point. Literature values from the same meta
           analysis1 will be used.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Functional outcome</measure>
    <time_frame>3 years follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>Functional outcome: hand function, strength (grip, key pinch &amp; tip pinch)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain</measure>
    <time_frame>5 years follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>- Subjective outcomes: postoperative pain data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hand function</measure>
    <time_frame>5 years follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>- functional outcomes at 1 and 5 years follow up after trapezio-metacarpal arthroplasty / trapeziectomy and trapeziectomy with LRTI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motion</measure>
    <time_frame>5 years follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>- ROM (palmar and radial abduction)at 1, 3 &amp; 5 years follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>5 years follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>- pre- and post Health Related QOL at 1, 3 &amp; 5 years follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic assessment</measure>
    <time_frame>5 years follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>- Incidence of Radiolucency lines at 1, 3 &amp; 5 years follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse event</measure>
    <time_frame>as requested</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>- frequency of postoperative adverse events</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Arthritis</condition>
  <arm_group>
    <arm_group_label>ARPE</arm_group_label>
    <description>Trapezio-metacarpal prosthesis ARPE</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ARPE</intervention_name>
    <arm_group_label>ARPE</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with trapezio-metacarpal arthritis Eaton Stage of trapezio-metacarpal arthritis :
        Stage II - IV
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with trapezio-metacarpal arthritis Eaton Stage of trapezio-metacarpal
             arthritis : Stage II - IV

          -  willing to return for follow up evaluation.

        Exclusion Criteria:

          -  local or systemic infections

          -  severe muscular, neurological or vascular deficiencies of the extremity involved

          -  bone destruction or poor bone to affect implant stability

          -  allergy to any of the components of the implant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederik VERSTREKEN, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SPM Deurne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frederik Verstreken, Dr</last_name>
    <email>frederik.verstreken@azmonica.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>SPM Deurne</name>
      <address>
        <city>Deurne</city>
        <zip>2100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederik Verstreken, PhD</last_name>
      <email>frederik.verstreken@azmonica.be</email>
    </contact>
    <investigator>
      <last_name>Frederik Verstreken, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>June 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>arthroplasty</keyword>
  <keyword>trapezio-metacarpial</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
